Join SAMHSA to Discuss the Report on Revised Regulations for Opioid Treatment Programs: Establishing a Baseline to Measure Progress Over Time Thursday, May 14, 1-2 p.m. ET

Join SAMHSA to Discuss the Report on Revised Regulations for Opioid Treatment Programs: Establishing a Baseline to Measure Progress Over Time Thursday, May 14, 1-2 p.m. ET SAMHSA's Center for Financing Reform and Innovation (CFRI) is releasing a report and hosting a webinar titled Revised Regulations for Opioid Treatment Programs: Establishing a Baseline to Measure Progress Over Time. https://westat.zoomgov.com/webinar/register/WN_inbu_-TlSpyvI9G47z_m0w?utm_source=SAMHSA&utm_campaign=825e2ccfea-EMAIL_CAMPAIGN_2026_05_05_02_48&utm_medium=email&utm_term=0_-825e2ccfea-167840245#/registration In 2024, revisions were made to 42 CFR part 8, the federal regulations that guide opioid treatment programs (OTPs). The revisions promote increased access to evidence-based medications for opioid use disorder (MOUD), greater retention in care by promoting practitioner's professional judgment in providing a patient-centered approach to care and reducing barriers to receiving services. Learn more about this report during SAMHSA’s webinar which examines the extent to which states/territories and OTPs have adopted the changes outlined in 42 CFR part 8 within the first year since the revised regulations were put into effect. Speakers include: Karran Phillips, M.D., MSc, Acting Director, Center for Substance Abuse Treatment (CSAT), SAMHSA – Opening Remarks Jennifer Caputo, Ph.D., Senior Research Associate, Westat – Welcome/Housekeeping Rikki Welch, M.A., Principal Research Associate, Westat – Report Overview Nichole Smith, MHSA, Chief, Regulatory Programs Branch, Division of Pharmacologic Therapies (DPT), CSAT, SAMHSA – Panel Moderator Patti Juliana, Ph.D., LCSW, Division Director, DPT, CSAT, SAMHSA – Panelist Adam Bucon, LSW, State Opioid Treatment Authority, New Jersey Department of Human Services, Division of Mental Health and Addiction Services – Panelist (Invited) Chrissie Martin, LMFT, LAC-S, CS, National Clinical Director – Midwest Division, Behavioral Health Group™ – Panelist Dustin Mets, J.D., Chief Executive Officer, CompDrug – Panelist